This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: A decrease of [18F]fluoro-l-dopa uptake in basal ganglia was recently reported in medically refractory epilepsy. The purpose of this study was to assess the involvement of dopaminergic neurotransmission in refractory temporal lobe epilepsy (TLE) and its relationship to glucose metabolism and morphologic changes.
Methods: Twelve TLE patients were studied using [18F]fluorodeoxyglucose PET, [18F]fluoro-l-dopa PET, and MRI and compared with healthy control volunteers. Morphologic cerebral changes were assessed using voxel-based morphometry. Student t test statistical maps of functional and morphologic differences between patients and controls were obtained using a general linear model.
Results: In TLE patients, [18F]fluoro-l-dopa uptake was reduced to the same extent in caudate and putamen in both cerebral hemispheres as well as in the substantia nigra (SN). These dopaminergic functional alterations occurred without any glucose metabolism changes in these areas. The only mild morphologic abnormality was found in striatal regions without any changes in the SN.
Conclusion: The present study provides support for dopaminergic neurotransmission involvement in temporal lobe epilepsy. The discrepancies between gray matter volume atrophy and the pattern of [18F]fluoro-l-dopa suggest that basal ganglia involvement is not related to structural subcortical abnormalities. A functional decrease can be ruled out because there was no change of the glycolytic pathway metabolism in these areas.
Glossary
- AED=
- antiepileptic drug;
- BG=
- basal ganglia;
- CBZ=
- carbamazepine;
- CLB=
- clobazam;
- DNET=
- dysembryoplastic neuroepitheliale tumor;
- FC=
- febrile convulsion; [18F]FDG ;
- FWHM=
- full-width at half-maximum;
- GBP=
- gabapentin;
- GMV=
- gray matter volume;
- GVB=
- vigabatrin;
- LHS=
- left hippocampal sclerosis;
- LTG=
- lamotrigine;
- OXC=
- oxcarbazepine;
- PB=
- phenobarbital;
- ROI=
- region of interest;
- SN=
- substantia nigra;
- TLE=
- temporal lobe epilepsy;
- TPM=
- topiramate;
- VPA=
- sodium valproate;
- WMV=
- white matter volume.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
- Basal ganglia involvement in temporal lobe epilepsy: A functional and morphologic study
- Reply from the authors
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.